logo
Uncertainty around NIH funding leaves Alzheimer's studies in limbo

Uncertainty around NIH funding leaves Alzheimer's studies in limbo

Yahoo24-04-2025

Zahydie Burgos Ribot and her husband, Francisco Rios, are checking items off their travel bucket list and spending quality time together before Francisco will no longer be able to travel – and before his brain forgets.
The Florida-based couple recently crossed Alaska off the list. Their next trip will be to Niagara Falls.
'We have a whole schedule,' Ribot said. 'We're choosing to live every single day with a lot of intention.'
That's because they know that Rios' window to easily create new memories is closing. About three years ago, at age 46, he was diagnosed with early-onset Alzheimer's disease.
Although Rios has been doing well on a new treatment he receives through a clinical trial, Ribot is increasingly afraid that the study could be hindered by cuts to federal funding of biomedical research.
The Trump administration has been conducting a restructuring of the US Department of Health and Human Services as well as a review of funding, resulting in the abrupt cancellation of hundreds of research grants under the National Institutes of Health and many others left in limbo, waiting for a decision on whether their funding will be renewed.
In March, 14 of 35 Alzheimer's Disease Research Centers had their funding halted by the NIH as the administration stopped $65 million in funding for research, according to Democratic lawmakers.
CNN has contacted HHS and the White House for comment.
'This is alarming, because these are critical data that inform not only prognosis but inform trajectory of the disease and inform future treatments,' Ribot said.
Rios also has been following these developments and remains worried about his future.
'He just asked me, 'Am I going to continue getting the trial?' But he was crying and literally ripping the skin off his fingers because of the anxiety,' Ribot said. 'He knows what's at stake. He is aware. He wants to continue the medication.'
Rios has been participating in a clinical trial conducted by Washington University in St. Louis in which he has been receiving the Alzheimer's drug Leqembi paired with an experimental therapy called E2814, given as intravenous infusions, to help slow his Alzheimer's symptoms.
Ribot credits the trial with helping curb Rios' memory loss and cognitive decline.
Before Rios was diagnosed, he began to emotionally withdraw and disconnect from loved ones. He even got lost while driving to a routine doctor's appointment about 10 minutes from their home, Ribot said.
She initially thought he was showing signs of depression. But Rios' doctor realized that something else was happening in his brain and referred him to the Young-Onset Dementias Clinic at Johns Hopkins in Baltimore.
'They ran more tests, and they ran the genetic testing, and that's when we had the final confirmation that it was Alzheimer's,' Ribot said.
If funding for Rios' clinical trial is curtailed, she said, not only could he and the other participants lose access to the medications that they hope are giving them more time to live normally, the development of other impactful Alzheimer's treatments could be delayed.
About a dozen Alzheimer's disease research centers are still waiting for their federal funding to be renewed, said Dr. Michael Greicius, professor of neurology and neurological sciences at the Stanford University School of Medicine, whose Alzheimer's center is among those awaiting a decision.
'Our five-year renewal was reviewed in October. Normally, we would have gotten a decision probably around February,' he said, adding that research funding for his team at the Stanford Alzheimer's Disease Research Center ran out about three weeks ago.
'It seems like we're moving towards renewal, but it's very hard to read the tea leaves, and that makes it really challenging when you're thinking about projects you'd like to undertake or hiring new research coordinators, for example,' he said.
Greicius and his colleagues had to hold off on starting research projects because they didn't know whether there will be funding coming in, he said.
The uncertainty around funding baffles him.
'It's hard to imagine a less political topic than Alzheimer's disease. I mean, it affects people from red states and blue states and purple states. It's so common. Almost everyone either has a relative in their family or at least has a friend who has a relative that's been affected by Alzheimer's disease,' Greicius said.
'It still seems like the easiest-to-agree-upon target for federally funded research, and yet it's not at all clear that this progress is going to continue,' he said. 'That, for me, is a large part of the frustration – just the uncertainty of it all.'
Preventive neurologist Dr. Richard Isaacson, founder of one of the first Alzheimer's prevention clinics in the United States, is also waiting to see whether his federal grants will be renewed.
'We're somewhere between limbo and purgatory,' he said.
Isaacson, who directs research at the Institute for Neurodegenerative Diseases in Florida, has developed free online software called RetainYourBrain, which aims to democratize access to brain health care. Users input their risk factors for Alzheimer's and receive a personalized risk assessment, as well as personalized recommendations and time-sensitive reminders on how to improve their brain health.
But without continued funding, 'it may never be released to the public,' Isaacson said.
Supporters of the funding cuts argue that the nation should reduce 'wasteful spending' and prioritize efficiency.
'With the government wanting to cut back on spending money, I get it. But Alzheimer's is one of the most expensive diseases to our health care system,' Isaacson said.
It's estimated that nearly 1 in every 6 Medicare dollars was spent on someone with the disease last year, according to the Alzheimer's Association, and the average per-person Medicare spending for older adults with Alzheimer's is estimated to be 2.8 times higher than average per-person spending for all other seniors.
'I feel that cutting Alzheimer's research that may save money over time, and doing it rapidly, is a bad investment,' Isaacson said.
While some studies are waiting to see if they'll continue, some studies have already had to take steps to shut down.
When the NIH canceled grants in March related to diversity, equity and inclusion, or DEI, some Alzheimer's studies were swept up in the consequences.
Federal funding for a multiyear study at the University of California, Davis' Alzheimer's Disease Research Center was abruptly terminated. This led the center's co-director, Dr. Charles DeCarli, to issue an appeal and fight to have the grant fully reinstated.
'The appeal had to be done within 30 days, and in the meantime, we had to shut down the study. So while I was working on the appeal, my team was doing all the things that closing a study needs to involve, which is hundreds of hours of work, notifying the 33 sites in this study,' he said.
DeCarli's appeal was successful. He won that battle but is still recovering from the turmoil.
'It was a very challenging month in my life,' DeCarli said. 'It just seems to me that the only reason that this was terminated is because it includes the word 'diverse' in the title.'
The study, titled 'The Clinical Significance of Incidental White Matter Lesions on MRI Amongst a Diverse Population with Cognitive Complaints (INDEED),' involves examining the effect that white matter injury in the brain and vascular issues may have on cognitive performance as well as health outcomes. The research was being funded by the NIH's National Institute of Neurological Disorders and Stroke.
Up to 25% of people who develop dementia later in life may have some type of vascular contributing factor to their disease, and DeCarli said his study could help 'lay out the foundation' for diagnostic tests and treatments for them.
'When these studies are terminated, an opportunity is lost to advance science,' he said.
Other studies may face similar threats to funding. According to a policy notice issued Monday, the NIH said it will begin pulling medical research funding from universities with diversity and inclusion programs and any boycotts of Israeli companies.
The agency 'reserves the right to terminate financial assistance awards and recover all funds' if grant recipients do not comply with federal guidelines barring diversity and equity research and 'prohibited boycotts,' the notice said.
The policy applies to 'domestic recipients of new, renewal, supplement, or continuation awards that are issued on or after' April 21, according to the notice.
Separately, the Washington-based nonprofit UsAgainstAlzheimer's has been tracking previously terminated grants and the funding cuts at the NIH that took place in March and earlier this month, and it warns that some cuts could stall the progress being made to find a cure for Alzheimer's disease.
'In the last 10 years, there have been groundbreaking advances in Alzheimer's disease research, in understanding where the disease comes from, and understanding how to diagnose the disease, and ultimately in how to treat the disease. But we don't have a cure yet,' said Russ Paulsen, chief operating officer at UsAgainstAlzheimer's.
'In looking through the list of grants that have been affected, it appears to cut across prevention, diagnosis, treatment and ultimately seeking a cure, as well as understanding the basics of the disease to start with,' he said. 'We've made huge progress, and now is not the time to take our foot off the accelerator.'
In the meantime, Ribot and Rios are trying to keep their heads up. They are keeping an eye on any new developments in research funding cuts while continuing to focus on their travel bucket list.
'While he's here and we're here, we're living our life. We are finding joy. Even when we cry, we laugh. Even when we are in despair, we have hope,' Ribot said.
'I'm not going to romanticize this disease, because that's not it – but there's still purpose and meaning and joy,' she said. 'We're not going to let this disease rob us of our present.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Honey Recall Map Shows Warnings Issued to Customers in 7 States
Honey Recall Map Shows Warnings Issued to Customers in 7 States

Newsweek

timean hour ago

  • Newsweek

Honey Recall Map Shows Warnings Issued to Customers in 7 States

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The Food and Drug Administration (FDA) has announced its classification of a recall of certain Comvita honey products, affecting seven states. Comvita, a California-based company, recalled three of its manuka honey products last month as the induction seal was not properly fitted, meaning the product was leaking on the packaging. Newsweek has contacted Comvita outside of regular working hours via email for comment. File photo: a teaspoon with a jar full of honey. File photo: a teaspoon with a jar full of honey. Oliver Berg/dpa via AP Why It Matters Maintaining packaging standards is important as it can make consumers feel more assured that companies have followed regulatory guidance more closely, and ensured their products are properly manufactured and controlled. Given that many Americans are concerned about food safety and food recalls, maintaining standards and regulations are even more important if brands want to establish consumer trust. What To Know The affected products include: Comvita's Manuka Honey + Lion's Mane for Focus (355g), with lot codes 34828522 and 34835584, and expiration dates of January 21, 2026 and February 21, 2026 respectively Comvita's Manuka Honey + Cordyceps for Energy (355g) with lot codes 34828523 and 34835585, and expiration dates of January 22, 2026 and February 25, 2026 respectively Comvita's Manuka Honey + Reishi (355g) with lot codes 34828521 and 34835574, and expiration dates of January 21, 2026 and February 24, 2026 respectively There were 2,730 units sold of each product, to various states including Colorado, Arizona, Texas, Maryland, Florida, California, and Georgia. Comvita initiated the recall on May 23, and the FDA announced its classification of the recall on June 9. The FDA classification of the recall was a Class II, meaning it is a situation "in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote." What People Are Saying Professor Byron Chaves, a professor and food safety extension specialist in the department of Food Science and Technology at the University of Nebraska-Lincoln, told Newsweek: "An induction seal is a protective seal commonly found on food containers, like jars or bottles, just under the cap. It's created using heat to attach a foil liner to the container's opening, forming a tight, tamper-evident seal. This helps prevent leaks, keeps the product fresh, and shows if the package has been opened." He added: "If an induction seal isn't properly applied, it can lead to leaks, contamination, and reduced shelf life. It also means the package may not show evident signs of tampering, which can raise safety concerns. In some cases, it could lead to regulatory issues or loss of consumer trust if the product appears unsafe or poorly sealed." What Happens Next Consumers are advised not to consume the affected products and return them to the place of purchase for a refund. As of June 9, the recall remains ongoing. The FDA did not specify if any illnesses had been reported in relation to the recall.

Woman Visits Gym Every Week, but There's a Twist: 'Need This'
Woman Visits Gym Every Week, but There's a Twist: 'Need This'

Newsweek

timean hour ago

  • Newsweek

Woman Visits Gym Every Week, but There's a Twist: 'Need This'

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A savvy woman has shared the only reason she goes to the gym once a week—and it isn't to work out. The TikTok clip, shared by @almillishit, has gathered 4.6 million views and 316,400 likes. It shows a spray tan machine, and the text overlaid explains that she pays $25 a month for a fitness membership "just to get a weekly spray and never actually work out." The Delaware-based woman told another user: "I'm genuinely so lucky [and] grateful." Some users expressed their envy, and said: "So jealous. Mine only has tanning booths!!!" Many users are impressed with the woman's money-saving hack, as the average cost of a spray tan is generally between $25 and $60, according to The Knot. "That's cheaper than the tanning bed I pay for at the salon each month," said one user, and another wrote: "Damn. I just paid $40 for one level 1 spray tan." "This should be it instead of the tanning beds," suggested a third user. In the comments, the woman tells another user that she is "scared" of sunbeds, most likely because sunlamps and sunbeds—including tanning beds and booths—are classified as known human carcinogens. A stock image of women using her phone in a gym. A stock image of women using her phone in a gym. Oscar Gutierrez Zozulia/iStock / Getty Images Plus Are Spray Tans Safe? According to the American Cancer Society, the amount and type of ultraviolet (UV) radiation a person receives from tanning beds depend on several factors: the type of lamps used, the duration of exposure, and the frequency of use. Most tanning beds primarily emit UVA rays, with a smaller proportion being UVB, which is a risk factor for all types of skin cancer. As a safer alternative, many people opt for sunless tanning methods such as fake tan products or sprays. These products work by interacting with proteins on the surface of the skin to create a temporary darkening effect, mimicking a natural tan. Like a real tan, the color gradually fades over several days. Most sunless tanning products contain an FDA-approved ingredient called dihydroxyacetone (DHA), a color additive used specifically for external application. When used correctly, these products are generally considered safe. However, the American Cancer Society cautions that DHA should only be used on the skin's surface and not: Inhaled through the nose or mouth. Ingested. Applied to areas with mucous membranes (such as the eyes, nose, or lips). If you're considering using a sunless tanning product, consult your doctor—especially if you have sensitive skin or health concerns. It's also important to note that most of these products do not provide sun protection. Even if a product contains sunscreen, its effectiveness typically lasts only a few hours. To reduce the risk of skin damage and skin cancer, continue using broad-spectrum sunscreen and wearing protective clothing when spending time outdoors. Newsweek has reached out to @almillishit for comment via email. We could not verify the details of the case. Do you have any clever hacks you use to make life easier (or cheaper) that you want to share? Send them to life@ with some details and they could appear in our Pet of the Week lineup.

Dr. Jay in the hot seat
Dr. Jay in the hot seat

Politico

timean hour ago

  • Politico

Dr. Jay in the hot seat

Presented by Driving the day WHAT TO DO WITH NIH'S UNSPENT FUNDS — President Donald Trump's cuts to ideologically disfavored research have left the National Institutes of Health with unspent funds. Director Jay Bhattacharya, under pressure from critics on Capitol Hill and in the research community, is pledging to change that. 'The biomedical research enterprise is being refocused and that's what will keep America at the forefront of global science, safety, and innovation,' HHS spokesperson Andrew Nixon said in a statement. The administration, Nixon confirmed, has targeted research Trump opposes on issues like transgender health care and health disparities among people of different races. Whether critics are satisfied in the end will depend not only on whether Bhattacharya follows through on his promise, but also on how he decides to spend the money. Thus far, neither he nor anyone in the Trump administration have laid out a detailed plan. By the numbers: A New York Times analysis found that the NIH had spent about $1.6 billion less between the time Trump took office Jan. 20 and the end of April compared to the same period the year before. Bhattacharya told advocates for research last month that he'd spend all of the agency's $48 billion budget for this year by the end of September. In the hot seat: Democrats will get a chance to ask Bhattacharya for more details when he testifies before a Senate Appropriations subcommittee this morning. Thus far, they've focused more on the cuts than on where the money will go, reflecting their view that Trump and his Department of Government Efficiency wanted to slash government spending, not target that spending on different priorities. Trump's budget proposal, released last month, suggested as much with its call for a 40 percent reduction in the NIH's total budget. The NIH is putting $500 million into a universal vaccine, which will target multiple strains of a virus. It also recently solicited proposals for autism research, with $50 million on offer. Last month, when Bhattacharya's boss, Health and Human Services Secretary Robert F. Kennedy Jr., testified before a House Appropriations subcommittee, ranking Democrat Rosa DeLauro of Connecticut pressed him: 'Are you planning to break the law by impounding congressionally appropriated funds?' Kennedy said no: 'If Congress appropriates me the money, I'm going to spend the money.' WELCOME TO TUESDAY PULSE. I'm Robert King, POLITICO's CMS reporter, filling in for Kelly today. It will be a busy week for health policy wonks as we wait for more news on whether the Senate makes changes to Medicaid in the 'big beautiful bill.' If you have any tips or news, don't hesitate to shoot me a message. Send tips, scoops and general thoughts to rking@ and khooper@ Follow along @rking_19 and @Kelhoops. AROUND THE AGENCIES RFK'S BOLDEST VACCINE STEP YET — HHS Secretary Robert F. Kennedy Jr. made his most dramatic move yet to overhaul vaccine approvals, firing all 17 members of the panel that advises the Centers for Disease Control and Prevention on vaccines. Kennedy said in an opinion piece for The Wall Street Journal that the Advisory Committee on Immunization Practices is rife with conflicts of interest and has acted as a rubber stamp for vaccines. This is the latest step for Kennedy, who has questioned the safety and effectiveness of vaccines, in changing how vaccines are approved and recommended by the federal government. He said in the op-ed that his goal is to restore faith in vaccines. It will now be up to Kennedy to pick new members to serve four-year terms on the panel, which votes on updates to CDC's vaccine schedule. The CDC director can override the recommendation but rarely does. His decision appears to contradict a promise he made to Sen. Bill Cassidy (R-La.) to secure the senator's vote for confirmation. Kennedy had promised to maintain ACIP 'without changes,' according to a speech Cassidy made on the Senate floor announcing his support for the nomination. Cassidy responded to the firings, writing on X that 'now the fear is that ACIP will be filled up with people who know nothing about vaccines except suspicion.' He added that he spoke with Kennedy and will continue to speak with him 'to ensure this is not the case.' Cassidy — who chairs the Senate Health, Education, Labor and Pensions Committee — later told reporters that the assurance he got from Kennedy was on the ACIP process rather than who sits on the panel. Sen. Susan Collins (R-Maine), who voted for Kennedy and sits on HELP, was taken by surprise. 'I don't know who serves on those committees, but it seems to be excessive to ask for everybody's resignations,' she told reporters. Congress TRYING TO STOP MEDICAID CUTS — More than 700 nursing home and assisted living professionals are heading to Capitol Hill this week to push lawmakers to avoid cuts to Medicaid in Republicans' megabill. The nursing home trade group American Health Care Association and National Center for Assisted Living will hold its annual congressional briefing this week. The fly-in day coincides with the last chance for advocates to push lawmakers for changes to the megabill. The group released a survey Monday of 363 nursing homes that found 79 percent were extremely concerned about Medicaid cuts. Another 55 percent would have to reduce their Medicaid patient population. One of the issues is a moratorium on provider taxes. A state can levy a tax on hospitals or other providers to pay for its share of Medicaid, which it jointly funds with the federal government. Under Medicaid, a state can get a higher payment from the federal government if it devotes more of its own resources. A state can use its provider tax revenue to get a higher federal payment and can replace the taxed amount from hospitals or nursing homes through a higher payment rate. The moratorium placed in the megabill, which passed the House last month, enables current provider taxes to continue but freezes any new rates. House Republicans have argued the taxes are a loophole that enable states to get more federal money, but the AHCA argued they are vital to keep nursing homes afloat. 'Restricting provider taxes is restricting resources to seniors and their caregivers,' said Clif Porter, president and CEO of the AHCA, in a statement. White House MCDONALDS, PEPSI HEAD TO WHITE HOUSE — The White House invited nearly 50 food industry and farm groups as well as major companies mentioned in a controversial report on how to Make America Health Again to meet with officials, POLITICO's Grace Yarrow reports. The list of invitees for the series of meetings includes lobbying heavyweights such as the National Cattlemen's Beef Association and American Farm Bureau Federation. Other invitees include soda brands Coca-Cola and Pepsi, as well as fast food representatives McDonald's and Yum! Brands, which own Taco Bell, KFC and others. The meetings are expected to take place this week and next. A May report from the MAHA Commission bashed farm groups for pesticide use. HHS has also called for a ban on sodas in federal nutrition programs. 'We're all very interested to see how these meetings play out over the next week and if it is a meaningful gesture or not,' said one agriculture industry insider. 'Is this just an exercise in placating stakeholders?' WHAT WE'RE READING The Washington Post reports on why Texas is spending millions to research an illegal psychedelic to jumpstart clinical trials. POLITICO's Benjamin Guggenheim reports on how Senate Finance Chair Mike Crapo is maneuvering behind closed doors to get his party's massive bill through the chamber. KFF Health News reports on when cannabis users age their health risks appear to grow.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store